AU702141B2 - Process for preparing enantiomerically pure tropic acid esters - Google Patents

Process for preparing enantiomerically pure tropic acid esters Download PDF

Info

Publication number
AU702141B2
AU702141B2 AU58120/96A AU5812096A AU702141B2 AU 702141 B2 AU702141 B2 AU 702141B2 AU 58120/96 A AU58120/96 A AU 58120/96A AU 5812096 A AU5812096 A AU 5812096A AU 702141 B2 AU702141 B2 AU 702141B2
Authority
AU
Australia
Prior art keywords
acid
tropic acid
reaction
optically active
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU58120/96A
Other versions
AU5812096A (en
Inventor
Rolf Banholzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of AU5812096A publication Critical patent/AU5812096A/en
Application granted granted Critical
Publication of AU702141B2 publication Critical patent/AU702141B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06Oxygen atoms
    • C07D451/10Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PCT No. PCT/EP96/01779 Sec. 371 Date Nov. 19, 1997 Sec. 102(e) Date Nov. 19, 1997 PCT Filed Apr. 26, 1996 PCT Pub. No. WO96/33996 PCT Pub. Date Oct. 31, 1996Precursors of anticholinergically active quaternary compounds can be synthesized from optically active tropic acid by acetylation, conversion into the acid chloride, reaction with amino alcohols of formula (I) (as the methanesulphonate; Q and R are explained in the specification), deacetylation and isolation of the reaction product.

Description

2 It has now been found that enantiomerically pure and (-)-tropic acid esters of amino alcohols of formula
II,
HO
(II)
wherein Q denotes CH2-CH 2
CH
2
-CH
2 CH=CH or CH CH, 0 R denotes a straight-chained or branched
CI-
4 -alkyl group, ~eS r can surprisingly be prepared by 25 o acetylating the corresponding optically active -tropic acid (HOCH2-
*HCOOH),
converting the resulting O-acetyl tropic acid with thionyl chloride into the acid chloride, reacting the latter at ambient temperature in an inert solvent, optionally with the addition of excess aluminium oxide, with the methanesulphonate of an amino alcohol of formula
I,
wherein R and Q are as defined above deacetylating the resulting compound by the action of a strong acid,and 3 isolating the optically active tropic acid ester obtained.
The and (-)-tropic acid required as starting material can be obtained from D,L-tropic acid by first preparing a salt with an optically active base in a manner known per se and recrystallising this salt several times. A suitable base might be, for example, (-)-quinine whilst the solvent for crystallisation might be ethanol. The (+)-tropic acid thus prepared has a purity of 99.8% 20 +73.1; c 1 in ethanol).
D
The reaction according to is preferably carried out at ambient temperature and the reaction according to (b) which is carried out immediately afterwards is preferably performed without intermediate isolation of the acetylated acid at ambient temperature or slightly elevated temperature.
Step takes place within a few days, when the methanesulphonate of a compound of formula is reacted in an inert solvent, such as methylene chloride, at temperatures between 0°C and about 30 0 C, preferably at ambient temperature, with stirring, whilst excess aluminium oxide may be used to bind the acid. Once the solvent has been eliminated under reduced pressure, the residue can be further processed directly.
In step favourable results are obtained if the deacetylation is carried out with a dilute aqueous inorganic acid, such as 2 20% hydrochloric acid, preferably 3 10% hydrochloric acid, at ambient temperature. Thus, for example, total reaction is obtained with 5% hydrochloric acid within about 2 days.
The reaction product can be isolated as a base (step by stirring the acidic reaction solution into 4 excess dilute 20%) sodium hydroxide solution or into aqueous alkali metal carbonate solution and filtering off the crystalline product precipitated.
Temperatures of between -15 and +50 0 C may be used; it is preferable to use sodium carbonate solution at about 0 C. The salts, e.g. the corresponding hydrochloride, can easily be prepared from the base by adding a stoichometric quantity of ethereal hydrochloric acid to the solution of the base, e.g. in methylene chloride.
The esters obtained in this way consist of more than 99% of the pure optically active compound, assuming that the starting acid is correspondingly pure.
The optically active esters which may be obtained according to the invention are valuable intermediate products for producing the corresponding anticholinergic quaternary compounds, such as the corresponding methobromides or methomethanesulphonates, which may be used, for example, as agents for treating asthmatic diseases or obstructive diseases of the respiratory tract.
The quaternary compounds may be prepared by conventional methods without racemisation.
The reaction according to the invention is explained more fully in the Examples which follow, but the reaction conditions according to the invention are not limited to the specific data provided.
5 Example 1 (-)-Tropic acid-N-isopropylnortropine ester hydrochloride 13.3 g of (-)-Tropic acid are added to 31.4 g of acetyl chloride with stirring and at ambient temperature and within one hour a clear solution is formed. After another hour, the reaction is virtually complete, according to thin layer chromatography (TLC). 47.5 g of thionyl chloride are added dropwise to the (-)-O-acetyl tropic acid solution over 30 minutes. The solution is stirred overnight at ambient temperature, then for a further hour at 50 0 C. After evaporation at 35 0 C under reduced pressure, 18.9 g of a brownish liquid remain, [a]20= -87.8 (c 0.5 in chloroform). The presence of
D
the desired compound can be confirmed by spectroscopy.
7.26 g (0.0275 mol) of N-isopropylnortropine methanesulphonate and 6.20 g (0.0275 mol) of the product obtained in are stirred in 45 ml of methylene chloride at ambient temperature. After seven days the reaction solution is evaporated down under reduced pressure at 30 0 C. The residue (16.9 g) is used for the next step without being further worked up.
11.1 g of the product according to are dissolved in 60 ml of 5% hydrochloric acid and stirred for 2 days at ambient temperature. TLC indicates quantitative deacetylation.
The reaction solution is extracted twice with a little diethylether, then any residual ether is eliminated under reduced pressure. Excess 20% aqueous sodium carbonate solution is then stirred into the solution, and a crystalline product is precipitated. It is filtered off and washed with cold water until the filtrate running away shows only a slightly alkaline reaction, and is then dissolved in methylene chloride.
6 After drying over sodium sulphate, the solvent is distilled off under reduced pressure and the residue is recrystallised from acetonitrile. White crystals are obtained, m.p. 131 0 C, [a] 20 -19.1 (c=1 in ethanol).
D
In order to prepare the hydrochloride, the solution of the base in methylene chloride is combined with the stoichiometric amount of ethereal hydrochloric acid.
After the product has been recrystallised from ethanol and acetonitrile, the (-)-tropic acid-N-isopropylnortropine ester hydrochloride is obtained in the form of white crystals, m.p. 214-8 0
C.
-27.8 (c=l in water); optical purity >99.8%.
The presence of the compound was confirmed by elemental analysis and spectroscopy.
Quaternisation to obtain the methobromide is carried out, for example, by reacting with methyl bromide in methylene chloride/acetonitrile at ambient temperature.
White crystals are obtained (yield 75.2% of theory, m.p.
20 238-42°C with decomposition).
[]20 -24.5 (c 1 in water); optical purity >99.5%.
The presence of the compound was confirmed by elemental analysis and spectroscopy.
9.
25 Example (+)-Tropic acid-N-isopropylnortropine esterhydrochloride Starting from (+)-tropic acid, which may be obtained by racemate cleaving from D,L-tropic acid with (-)-quinine, +73.1 (c 1 in ethanol; optical purity 99.8%), the title compound is obtained analogously to Example 1 in the form of white crystals, m.p. 214-7 0 C, with decomposition, [a]2 0 +27.8 (c 1 in water). Yield 55.7% of theory. Once again, the presence of the compound is confirmed by elemental analysis and spectroscopy.
7 As described in Example 1; the compound obtained is reacted to form the methobromide; m.p. 238-41 0
C
(decomp.), [a] 2 0 +25.3 (c 1 in water).
D
For reacting the O-acetyltropic acid chlorides with the compounds yields of between 60 and 70% are obtained if the reactions continue at room temperature for several days, and in addition to methylene chloride, for example, dimethylformamide or acetonitrile as reaction medium will give similar results.
8 THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: i. Process for preparing enantiomerically pure and (-)-tropic acid esters of amino alcohols of formula
II,
100 HO 0
(II)
wherein Q denotes
CH
2 -CH2,
CH
2
-CH
2
-CH
2 CH=CH or CH -CH, 0 *i R denotes a straight-chained or branched Cx.
4 -alkyl 20 group, characterised in that the corresponding optically active tropic acid is 25 acetylated, the resulting O-acetyltropic acid is converted with thionyl chloride into the acid chloride, the latter is reacted at ambient temperature in an inert solvent with the methanesulphonate of an amino alcohol of formula HO R-N
(I)
wherein R and Q are as defined above wherein R and Q are as defined above deacetylating the resulting compound by the action of a strong acid,and

Claims (1)

  1. 9- the resulting optically active tropic acid ester is isolated. 2. Process according to claim 1 characterised in that the reaction is carried out in the presence of excess aluminium oxide. 3. Process according to claim 1 characterised in that the optically active tropic acid ester is precipitated from the acid solution using aqueous sodium carbonate solution. 4. Process according to claims 1 to 3, characterised S in that N-isopropylnortropine methanesulphonate is used as the compound of formula 5. Process according to any one of claims 1 to 4 substantially as hereinbefore described with reference to the Examples. •go 10 Precursors of anticholinergically active quaternary compounds can be synthesised from optically active tropic acid by acetylation, conversion into the acid chloride, reaction with amino alcohols of formula (I) H-O- R-N (I) (as the methanesulphonate; Q and R are explained in the specification), deacetylation and isolation of the reaction product.
AU58120/96A 1995-04-28 1996-04-29 Process for preparing enantiomerically pure tropic acid esters Ceased AU702141B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19515625A DE19515625C2 (en) 1995-04-28 1995-04-28 Process for the production of enantiomerically pure tropic acid esters
DE19515625 1995-04-28
PCT/EP1996/001779 WO1996033996A1 (en) 1995-04-28 1996-04-29 Process for preparing pure enantiomers of tropic acid esters

Publications (2)

Publication Number Publication Date
AU5812096A AU5812096A (en) 1996-11-18
AU702141B2 true AU702141B2 (en) 1999-02-11

Family

ID=7760581

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58120/96A Ceased AU702141B2 (en) 1995-04-28 1996-04-29 Process for preparing enantiomerically pure tropic acid esters

Country Status (27)

Country Link
US (1) US5952505A (en)
EP (1) EP0822935B1 (en)
JP (1) JP3988056B2 (en)
KR (1) KR100386383B1 (en)
CN (1) CN1050357C (en)
AT (1) ATE208389T1 (en)
AU (1) AU702141B2 (en)
BG (1) BG62209B1 (en)
BR (1) BR9608288A (en)
CZ (1) CZ292579B6 (en)
DE (2) DE19515625C2 (en)
DK (1) DK0822935T3 (en)
EE (1) EE03398B1 (en)
ES (1) ES2167573T3 (en)
HK (1) HK1010878A1 (en)
HU (1) HU228037B1 (en)
MX (1) MX9708211A (en)
NO (1) NO316175B1 (en)
NZ (1) NZ308462A (en)
PL (1) PL183118B1 (en)
PT (1) PT822935E (en)
RO (1) RO118871B1 (en)
RU (1) RU2162850C2 (en)
SK (1) SK283793B6 (en)
TR (1) TR199701266T1 (en)
TW (1) TW413680B (en)
WO (1) WO1996033996A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033920A2 (en) 1997-01-31 1998-08-06 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
HUP0300832A2 (en) * 2000-04-27 2003-08-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel, slow-acting betamimetics, a method for their production and their use as medicaments and pharmaceutical compositions containing them
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
KR100488644B1 (en) * 2000-10-12 2005-05-11 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 Novel tiotropium-containing inhalation powder
US6706726B2 (en) 2000-10-14 2004-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics which may be used as medicaments as well as processes for preparing them
US6852728B2 (en) * 2000-10-14 2005-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them
US20020111363A1 (en) * 2000-10-31 2002-08-15 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
DE10062712A1 (en) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics and corticosteroids
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US20020193392A1 (en) * 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
US20030013675A1 (en) * 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
US20030070679A1 (en) * 2001-06-01 2003-04-17 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US6610849B2 (en) * 2001-06-28 2003-08-26 Boehringer Ingelheim Pharma Kg Process for the manufacture of tropenol
DE10141377A1 (en) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Scattering process for the production of powder formulations
US6919325B2 (en) * 2001-09-14 2005-07-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts
DE10200943A1 (en) 2002-01-12 2003-07-24 Boehringer Ingelheim Pharma Process for the preparation of scopine esters
US7405224B2 (en) * 2002-01-31 2008-07-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions
US6790856B2 (en) * 2002-01-31 2004-09-14 Boehringer Ingelheim Pharma Kg Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
US7309707B2 (en) * 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
DE10212264A1 (en) * 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Crystalline micronisate, process for its preparation and its use for the manufacture of a medicament
US7311894B2 (en) * 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
US7244415B2 (en) * 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
ATE339951T1 (en) * 2002-04-04 2006-10-15 Boehringer Ingelheim Pharma POWDER PREPARATIONS FOR INHALATION
US20030235538A1 (en) 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
US7417051B2 (en) * 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
US7084153B2 (en) * 2002-04-12 2006-08-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising steroids and a novel anticholinergic
US7763280B2 (en) * 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
DE10345065A1 (en) * 2003-09-26 2005-04-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol formulation for inhalation containing an anticholinergic
SE0303570L (en) * 2003-12-03 2005-06-04 Microdrug Ag Moisture-sensitive medical product
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
WO2011099265A1 (en) * 2010-02-12 2011-08-18 パナソニック株式会社 Plasma display panel
US20120080478A1 (en) 2010-09-30 2012-04-05 Ethicon Endo-Surgery, Inc. Surgical staple cartridges with detachable support structures and surgical stapling instruments with systems for preventing actuation motions when a cartridge is not present
CN103387534B (en) * 2012-05-09 2015-02-18 北大方正集团有限公司 Method for separating tropicamide raceme
CN104628718A (en) * 2014-06-11 2015-05-20 苏州景泓生物技术有限公司 Method for synthesizing scopolamine and salts thereof
CN115572290A (en) * 2022-09-06 2023-01-06 河北仁合益康药业有限公司 Method for synthesizing ipratropium bromide by one-pot method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1289429A (en) * 1960-03-10 1962-04-06 Lepetit Spa Process for the preparation of the new esters of tropine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1289429A (en) * 1960-03-10 1962-04-06 Lepetit Spa Process for the preparation of the new esters of tropine

Also Published As

Publication number Publication date
NO974967L (en) 1997-10-27
CZ292579B6 (en) 2003-10-15
BG101948A (en) 1998-05-29
SK144497A3 (en) 1998-03-04
ATE208389T1 (en) 2001-11-15
CN1183098A (en) 1998-05-27
NO316175B1 (en) 2003-12-22
DE19515625A1 (en) 1996-10-31
JP3988056B2 (en) 2007-10-10
HK1010878A1 (en) 1999-07-02
US5952505A (en) 1999-09-14
KR100386383B1 (en) 2003-09-19
SK283793B6 (en) 2004-01-08
BR9608288A (en) 1999-06-29
CZ340597A3 (en) 1998-01-14
EP0822935B1 (en) 2001-11-07
RO118871B1 (en) 2003-12-30
HUP9802210A2 (en) 1999-02-01
CN1050357C (en) 2000-03-15
WO1996033996A1 (en) 1996-10-31
PL183118B1 (en) 2002-05-31
TW413680B (en) 2000-12-01
KR19990008072A (en) 1999-01-25
DK0822935T3 (en) 2001-12-27
BG62209B1 (en) 1999-05-31
PT822935E (en) 2002-04-29
HUP9802210A3 (en) 2000-03-28
TR199701266T1 (en) 1998-02-21
DE19515625C2 (en) 1998-02-19
AU5812096A (en) 1996-11-18
EE9700262A (en) 1998-06-15
ES2167573T3 (en) 2002-05-16
DE59608148D1 (en) 2001-12-13
HU228037B1 (en) 2012-08-28
PL323038A1 (en) 1998-03-02
JPH11504027A (en) 1999-04-06
MX9708211A (en) 1997-12-31
NO974967D0 (en) 1997-10-27
RU2162850C2 (en) 2001-02-10
EP0822935A1 (en) 1998-02-11
EE03398B1 (en) 2001-04-16
NZ308462A (en) 1999-01-28

Similar Documents

Publication Publication Date Title
AU702141B2 (en) Process for preparing enantiomerically pure tropic acid esters
SU1301313A3 (en) Method for producing substituted 2-mercapto-imidazoles
EP0452143B1 (en) Process for preparing optically active 3-hydroxypyrrolidine derivatives
SU843749A3 (en) Method of preparing 4a,9b-trans-hexahydro-gamma-carboline
HU195764B (en) Process for production of optically active carnitinenitril-chloride
CA2219533C (en) Process for preparing enantiomerically pure tropic acid esters
EP0035811B1 (en) Process for resolving dl-s-benzoyl-beta-mercaptoisobutyric acid, and products obtained by applying this process
IL118660A (en) Process for preparing enantiomerically pure tropic acid esters
HU213315B (en) Process for producing arylacetic acids and their alkali metal salts
US4816580A (en) Improved method for preparing penicillanic acid derivatives
AU2008202097A1 (en) A Process for the Preparation of Keto Compounds
SK19993A3 (en) Process for preparing 1-(3-mercapto-(2s)-methyl-propionyl)- -l-proline
CA1120493A (en) Process for producing 4&#39;-(2-carboxy-ethyl)phenyl trans-4-aminomethylcyclohexanecarboxylate or the acid-addition salts thereof and intermediates for producing the same
US20040039206A1 (en) Process for resolving racemic mixtures of piperidine derivatives
JPS61140554A (en) Use of alkyl n-maleylphenylalanate and manufacture
KR100952489B1 (en) Cis-2,6-disubstituted tetrahydropyran derivatives and their preparation method
JPS62167754A (en) Production of cyanomethylthioacetic acids
KR830000950B1 (en) Method for preparing benzoic acid derivatives
KR790000983B1 (en) Process for preparing of pthalidylester of aminobenzyl penicillanic acid
JPH10316605A (en) Production of 3-substituted-1-propanol
IL150621A (en) Method for producing aryl-iminomethyl-carbamic acid esters
JPH0121832B2 (en)
JPS58203974A (en) Optically active imidazolylpropanediol derivative and its preparation
JPS5929631A (en) Preparation of phenylacetones
CS257300B2 (en) Production method of 4-hydroxy-2-oxo-pyrrolidin-1-yl-acetamide